"Chris has made broad contributions as a member of the CytomX executive team and is a proven crossfunctional leader within the organization," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "We are excited to announce this promotion, which is a reflection of Chris' financial acumen, strategic leadership and deep commitment to CytomX's mission." About CytomX Therapeutics This press release includes forward-looking statements. Such forward-looking statements involve known and unkn ...

When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience. This doesn't mean you must choose from well-known tickers. Even if a penny stock comes from a publicly traded company with genuine potential, everything from macroeconomic trends to legal actions can bring down the company. It's important to remember that every com ...

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants. The stock options were granted pursuant to the Company's 2019 Employment ...

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants. The stock options were granted pursuant to the Company's 2019 Employment ...

CytomX Therapeutics (NASDAQ:CTMX) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company.CytomX Therapeutics’ latest clinical trial update covers its Phase 1a study of CX-904, a cancer treatment in development. The company notes that the current results show a favorable safety profile and anti-cancer activity.However, diving into the data better explains why investors aren’t happy. Of the six pancreatic cancer patients able to be evaluated ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Results Conference Call May 8, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Wayne Chu - Chief Medical Officer Conference Call Participants Peter Lawson - Barclays Roger Song - Jefferies Joe Catanzaro - Piper Sandler Etzer Darout - BMO Capital Markets Anupam Rama - JPMorgan Mitchell Kapoor - H. C. Wainwright Operator Good day, and thank you for standing by. ...

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, including the execution of a clinical collaboration agreement with Merck to supply KEYTRUDA® (pembrolizumab ...

Exhibit 99.1 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T- cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, ...

As of the cutoff date, CX-904 demonstrated a favorable safety profile that supports administration and monitoring of enrolled patients in an outpatient setting. 1 There were no observed cases of cytokine release syndrome (CRS) of any grade in step-dosing cohorts as of the cutoff date. In non-step dosing cohorts, only Grade 1 CRS was observed in patients treated at the highest dose of 6 mg. Overall, the most common treatment-related adverse events (TRAEs) were rash, arthralgia, arthritis, pruritis, and vomit ...

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -                   - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma - SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- CytomX Ther ...